nodes	percent_of_prediction	percent_of_DWPC	metapath
Levobupivacaine—SCN10A—melanoma	0.578	1	CbGaD
Levobupivacaine—CYP1A2—Carmustine—melanoma	0.0789	0.27	CbGbCtD
Levobupivacaine—CYP1A2—Vemurafenib—melanoma	0.0624	0.213	CbGbCtD
Levobupivacaine—CYP3A4—Temozolomide—melanoma	0.0597	0.204	CbGbCtD
Levobupivacaine—CYP1A2—Dacarbazine—melanoma	0.0478	0.163	CbGbCtD
Levobupivacaine—CYP3A4—Vemurafenib—melanoma	0.0327	0.112	CbGbCtD
Levobupivacaine—CYP3A4—Docetaxel—melanoma	0.0112	0.0383	CbGbCtD
Levobupivacaine—Tocainide—SCN11A—melanoma	0.00171	0.291	CrCbGaD
Levobupivacaine—Mepivacaine—SCN10A—melanoma	0.000864	0.148	CrCbGaD
Levobupivacaine—Bupivacaine—SCN10A—melanoma	0.000847	0.145	CrCbGaD
Levobupivacaine—Ropivacaine—SCN10A—melanoma	0.000683	0.117	CrCbGaD
Levobupivacaine—Tocainide—SCN10A—melanoma	0.000642	0.11	CrCbGaD
Levobupivacaine—Lidocaine—SCN10A—melanoma	0.000496	0.0848	CrCbGaD
Levobupivacaine—Erythema—Vemurafenib—melanoma	0.000454	0.00544	CcSEcCtD
Levobupivacaine—Back pain—Vemurafenib—melanoma	0.000439	0.00526	CcSEcCtD
Levobupivacaine—Lethargy—Dactinomycin—melanoma	0.000434	0.00521	CcSEcCtD
Levobupivacaine—Injury—Carmustine—melanoma	0.000434	0.0052	CcSEcCtD
Levobupivacaine—Rigors—Docetaxel—melanoma	0.000432	0.00518	CcSEcCtD
Levobupivacaine—Vascular purpura—Temozolomide—melanoma	0.00043	0.00516	CcSEcCtD
Levobupivacaine—Extravasation—Docetaxel—melanoma	0.000404	0.00485	CcSEcCtD
Levobupivacaine—Purpura—Temozolomide—melanoma	0.0004	0.00479	CcSEcCtD
Levobupivacaine—Diplopia—Carmustine—melanoma	0.000398	0.00478	CcSEcCtD
Levobupivacaine—Cough—Vemurafenib—melanoma	0.000396	0.00475	CcSEcCtD
Levobupivacaine—Bone disorder—Docetaxel—melanoma	0.000391	0.00468	CcSEcCtD
Levobupivacaine—Bronchospasm—Bleomycin—melanoma	0.000388	0.00465	CcSEcCtD
Levobupivacaine—Arthralgia—Vemurafenib—melanoma	0.000386	0.00463	CcSEcCtD
Levobupivacaine—Diplopia—Temozolomide—melanoma	0.000385	0.00462	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000384	0.0046	CcSEcCtD
Levobupivacaine—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000383	0.0046	CcSEcCtD
Levobupivacaine—Blood bilirubin increased—Docetaxel—melanoma	0.000373	0.00447	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Vemurafenib—melanoma	0.00037	0.00444	CcSEcCtD
Levobupivacaine—Dysphagia—Dactinomycin—melanoma	0.000368	0.00441	CcSEcCtD
Levobupivacaine—Infection—Vemurafenib—melanoma	0.000368	0.00441	CcSEcCtD
Levobupivacaine—Nervous system disorder—Vemurafenib—melanoma	0.000363	0.00436	CcSEcCtD
Levobupivacaine—Skin disorder—Vemurafenib—melanoma	0.00036	0.00431	CcSEcCtD
Levobupivacaine—Respiratory failure—Docetaxel—melanoma	0.000359	0.00431	CcSEcCtD
Levobupivacaine—Lidocaine—EGFR—melanoma	0.000358	0.0612	CrCbGaD
Levobupivacaine—Blood pressure increased—Docetaxel—melanoma	0.000353	0.00423	CcSEcCtD
Levobupivacaine—Muscular weakness—Carmustine—melanoma	0.000351	0.00421	CcSEcCtD
Levobupivacaine—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000347	0.00416	CcSEcCtD
Levobupivacaine—Hypotension—Vemurafenib—melanoma	0.000346	0.00415	CcSEcCtD
Levobupivacaine—Dysphagia—Carmustine—melanoma	0.000344	0.00413	CcSEcCtD
Levobupivacaine—Muscular weakness—Temozolomide—melanoma	0.00034	0.00407	CcSEcCtD
Levobupivacaine—Alanine aminotransferase increased—Temozolomide—melanoma	0.00034	0.00407	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000337	0.00405	CcSEcCtD
Levobupivacaine—Haematuria—Bleomycin—melanoma	0.000335	0.00402	CcSEcCtD
Levobupivacaine—Abdominal distension—Temozolomide—melanoma	0.000335	0.00402	CcSEcCtD
Levobupivacaine—Dysphagia—Temozolomide—melanoma	0.000333	0.00399	CcSEcCtD
Levobupivacaine—Neuropathy—Docetaxel—melanoma	0.000331	0.00397	CcSEcCtD
Levobupivacaine—Sweating increased—Temozolomide—melanoma	0.000324	0.00389	CcSEcCtD
Levobupivacaine—Decreased appetite—Vemurafenib—melanoma	0.000322	0.00386	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00032	0.00383	CcSEcCtD
Levobupivacaine—Constipation—Vemurafenib—melanoma	0.000317	0.0038	CcSEcCtD
Levobupivacaine—Lightheadedness—Docetaxel—melanoma	0.000316	0.00379	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Bleomycin—melanoma	0.000314	0.00377	CcSEcCtD
Levobupivacaine—Pulmonary oedema—Docetaxel—melanoma	0.000314	0.00377	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Carmustine—melanoma	0.000301	0.00361	CcSEcCtD
Levobupivacaine—Urinary tract infection—Carmustine—melanoma	0.000298	0.00358	CcSEcCtD
Levobupivacaine—Infestation NOS—Temozolomide—melanoma	0.000297	0.00356	CcSEcCtD
Levobupivacaine—Infestation—Temozolomide—melanoma	0.000297	0.00356	CcSEcCtD
Levobupivacaine—Flushing—Bleomycin—melanoma	0.000293	0.00352	CcSEcCtD
Levobupivacaine—Body temperature increased—Vemurafenib—melanoma	0.000293	0.00351	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Temozolomide—melanoma	0.000291	0.00349	CcSEcCtD
Levobupivacaine—Urinary tract infection—Temozolomide—melanoma	0.000288	0.00346	CcSEcCtD
Levobupivacaine—Chills—Bleomycin—melanoma	0.000283	0.0034	CcSEcCtD
Levobupivacaine—Erythema—Bleomycin—melanoma	0.000275	0.0033	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Carmustine—melanoma	0.000274	0.00329	CcSEcCtD
Levobupivacaine—Flushing—Dactinomycin—melanoma	0.000273	0.00328	CcSEcCtD
Levobupivacaine—Hypersensitivity—Vemurafenib—melanoma	0.000273	0.00327	CcSEcCtD
Levobupivacaine—Oedema peripheral—Carmustine—melanoma	0.000272	0.00326	CcSEcCtD
Levobupivacaine—Asthenia—Vemurafenib—melanoma	0.000266	0.00319	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Temozolomide—melanoma	0.000265	0.00318	CcSEcCtD
Levobupivacaine—Chills—Dactinomycin—melanoma	0.000264	0.00317	CcSEcCtD
Levobupivacaine—Oedema peripheral—Temozolomide—melanoma	0.000262	0.00315	CcSEcCtD
Levobupivacaine—Pruritus—Vemurafenib—melanoma	0.000262	0.00314	CcSEcCtD
Levobupivacaine—Lethargy—Docetaxel—melanoma	0.000261	0.00313	CcSEcCtD
Levobupivacaine—Erythema—Dactinomycin—melanoma	0.000256	0.00307	CcSEcCtD
Levobupivacaine—Flushing—Carmustine—melanoma	0.000256	0.00307	CcSEcCtD
Levobupivacaine—Anaemia—Bleomycin—melanoma	0.000254	0.00305	CcSEcCtD
Levobupivacaine—Diarrhoea—Vemurafenib—melanoma	0.000253	0.00304	CcSEcCtD
Levobupivacaine—Tinnitus—Temozolomide—melanoma	0.000248	0.00298	CcSEcCtD
Levobupivacaine—Flushing—Temozolomide—melanoma	0.000247	0.00297	CcSEcCtD
Levobupivacaine—Cardiac disorder—Temozolomide—melanoma	0.000247	0.00297	CcSEcCtD
Levobupivacaine—Arrhythmia—Carmustine—melanoma	0.000246	0.00295	CcSEcCtD
Levobupivacaine—Dizziness—Vemurafenib—melanoma	0.000245	0.00294	CcSEcCtD
Levobupivacaine—Mental disorder—Carmustine—melanoma	0.000242	0.0029	CcSEcCtD
Levobupivacaine—Erythema—Carmustine—melanoma	0.00024	0.00288	CcSEcCtD
Levobupivacaine—Malnutrition—Carmustine—melanoma	0.00024	0.00288	CcSEcCtD
Levobupivacaine—Cough—Bleomycin—melanoma	0.00024	0.00288	CcSEcCtD
Levobupivacaine—Chills—Temozolomide—melanoma	0.000239	0.00287	CcSEcCtD
Levobupivacaine—Anaemia—Dactinomycin—melanoma	0.000237	0.00284	CcSEcCtD
Levobupivacaine—Vomiting—Vemurafenib—melanoma	0.000235	0.00282	CcSEcCtD
Levobupivacaine—Orthostatic hypotension—Docetaxel—melanoma	0.000234	0.00281	CcSEcCtD
Levobupivacaine—Mental disorder—Temozolomide—melanoma	0.000233	0.0028	CcSEcCtD
Levobupivacaine—Back pain—Carmustine—melanoma	0.000232	0.00278	CcSEcCtD
Levobupivacaine—Headache—Vemurafenib—melanoma	0.000232	0.00278	CcSEcCtD
Levobupivacaine—Malnutrition—Temozolomide—melanoma	0.000232	0.00278	CcSEcCtD
Levobupivacaine—Erythema—Temozolomide—melanoma	0.000232	0.00278	CcSEcCtD
Levobupivacaine—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000231	0.00277	CcSEcCtD
Levobupivacaine—Confusional state—Bleomycin—melanoma	0.000226	0.00271	CcSEcCtD
Levobupivacaine—Vision blurred—Carmustine—melanoma	0.000226	0.00271	CcSEcCtD
Levobupivacaine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000226	0.00271	CcSEcCtD
Levobupivacaine—Tremor—Carmustine—melanoma	0.000225	0.0027	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Bleomycin—melanoma	0.000224	0.00269	CcSEcCtD
Levobupivacaine—Oedema—Bleomycin—melanoma	0.000224	0.00269	CcSEcCtD
Levobupivacaine—Back pain—Temozolomide—melanoma	0.000224	0.00269	CcSEcCtD
Levobupivacaine—Infection—Bleomycin—melanoma	0.000223	0.00267	CcSEcCtD
Levobupivacaine—Anaemia—Carmustine—melanoma	0.000222	0.00266	CcSEcCtD
Levobupivacaine—Dysphagia—Docetaxel—melanoma	0.000221	0.00265	CcSEcCtD
Levobupivacaine—Agitation—Carmustine—melanoma	0.000221	0.00264	CcSEcCtD
Levobupivacaine—Nausea—Vemurafenib—melanoma	0.00022	0.00264	CcSEcCtD
Levobupivacaine—Vision blurred—Temozolomide—melanoma	0.000219	0.00262	CcSEcCtD
Levobupivacaine—Bronchospasm—Docetaxel—melanoma	0.000218	0.00261	CcSEcCtD
Levobupivacaine—Tremor—Temozolomide—melanoma	0.000217	0.00261	CcSEcCtD
Levobupivacaine—Anaemia—Temozolomide—melanoma	0.000214	0.00257	CcSEcCtD
Levobupivacaine—Agitation—Temozolomide—melanoma	0.000213	0.00256	CcSEcCtD
Levobupivacaine—Angioedema—Temozolomide—melanoma	0.000212	0.00254	CcSEcCtD
Levobupivacaine—Hypotension—Bleomycin—melanoma	0.00021	0.00251	CcSEcCtD
Levobupivacaine—Oedema—Dactinomycin—melanoma	0.000209	0.00251	CcSEcCtD
Levobupivacaine—Convulsion—Carmustine—melanoma	0.000208	0.00249	CcSEcCtD
Levobupivacaine—Infection—Dactinomycin—melanoma	0.000208	0.00249	CcSEcCtD
Levobupivacaine—Hypertension—Carmustine—melanoma	0.000207	0.00248	CcSEcCtD
Levobupivacaine—Palpitations—Temozolomide—melanoma	0.000205	0.00246	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000204	0.00245	CcSEcCtD
Levobupivacaine—Anxiety—Carmustine—melanoma	0.000204	0.00244	CcSEcCtD
Levobupivacaine—Cough—Temozolomide—melanoma	0.000202	0.00243	CcSEcCtD
Levobupivacaine—Paraesthesia—Bleomycin—melanoma	0.000201	0.00242	CcSEcCtD
Levobupivacaine—Convulsion—Temozolomide—melanoma	0.000201	0.00241	CcSEcCtD
Levobupivacaine—Hypertension—Temozolomide—melanoma	0.0002	0.0024	CcSEcCtD
Levobupivacaine—Dyspnoea—Bleomycin—melanoma	0.0002	0.0024	CcSEcCtD
Levobupivacaine—Confusional state—Carmustine—melanoma	0.000197	0.00237	CcSEcCtD
Levobupivacaine—Arthralgia—Temozolomide—melanoma	0.000197	0.00237	CcSEcCtD
Levobupivacaine—Infestation—Docetaxel—melanoma	0.000197	0.00237	CcSEcCtD
Levobupivacaine—Infestation NOS—Docetaxel—melanoma	0.000197	0.00237	CcSEcCtD
Levobupivacaine—Anxiety—Temozolomide—melanoma	0.000197	0.00236	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000196	0.00235	CcSEcCtD
Levobupivacaine—Oedema—Carmustine—melanoma	0.000196	0.00235	CcSEcCtD
Levobupivacaine—Decreased appetite—Bleomycin—melanoma	0.000195	0.00234	CcSEcCtD
Levobupivacaine—Infection—Carmustine—melanoma	0.000195	0.00233	CcSEcCtD
Levobupivacaine—Neuropathy peripheral—Docetaxel—melanoma	0.000193	0.00232	CcSEcCtD
Levobupivacaine—Pain—Bleomycin—melanoma	0.000192	0.0023	CcSEcCtD
Levobupivacaine—Tachycardia—Carmustine—melanoma	0.000191	0.00229	CcSEcCtD
Levobupivacaine—Confusional state—Temozolomide—melanoma	0.000191	0.00229	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000191	0.00229	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Temozolomide—melanoma	0.000189	0.00227	CcSEcCtD
Levobupivacaine—Oedema—Temozolomide—melanoma	0.000189	0.00227	CcSEcCtD
Levobupivacaine—Infection—Temozolomide—melanoma	0.000188	0.00225	CcSEcCtD
Levobupivacaine—Nervous system disorder—Temozolomide—melanoma	0.000186	0.00223	CcSEcCtD
Levobupivacaine—Feeling abnormal—Bleomycin—melanoma	0.000185	0.00222	CcSEcCtD
Levobupivacaine—Skin disorder—Temozolomide—melanoma	0.000184	0.0022	CcSEcCtD
Levobupivacaine—Hypotension—Carmustine—melanoma	0.000183	0.00219	CcSEcCtD
Levobupivacaine—Hyperhidrosis—Temozolomide—melanoma	0.000183	0.00219	CcSEcCtD
Levobupivacaine—Decreased appetite—Dactinomycin—melanoma	0.000182	0.00218	CcSEcCtD
Levobupivacaine—Pain—Dactinomycin—melanoma	0.000179	0.00215	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Carmustine—melanoma	0.000178	0.00214	CcSEcCtD
Levobupivacaine—Urticaria—Bleomycin—melanoma	0.000178	0.00214	CcSEcCtD
Levobupivacaine—Body temperature increased—Bleomycin—melanoma	0.000177	0.00213	CcSEcCtD
Levobupivacaine—Insomnia—Carmustine—melanoma	0.000177	0.00212	CcSEcCtD
Levobupivacaine—Hypoaesthesia—Docetaxel—melanoma	0.000176	0.00211	CcSEcCtD
Levobupivacaine—Paraesthesia—Carmustine—melanoma	0.000176	0.00211	CcSEcCtD
Levobupivacaine—Dyspnoea—Carmustine—melanoma	0.000175	0.00209	CcSEcCtD
Levobupivacaine—Oedema peripheral—Docetaxel—melanoma	0.000175	0.00209	CcSEcCtD
Levobupivacaine—Somnolence—Carmustine—melanoma	0.000174	0.00209	CcSEcCtD
Levobupivacaine—Feeling abnormal—Dactinomycin—melanoma	0.000172	0.00207	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000172	0.00207	CcSEcCtD
Levobupivacaine—Insomnia—Temozolomide—melanoma	0.000171	0.00205	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Dactinomycin—melanoma	0.000171	0.00205	CcSEcCtD
Levobupivacaine—Decreased appetite—Carmustine—melanoma	0.00017	0.00204	CcSEcCtD
Levobupivacaine—Paraesthesia—Temozolomide—melanoma	0.00017	0.00204	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Carmustine—melanoma	0.000169	0.00203	CcSEcCtD
Levobupivacaine—Dyspnoea—Temozolomide—melanoma	0.000169	0.00202	CcSEcCtD
Levobupivacaine—Somnolence—Temozolomide—melanoma	0.000168	0.00202	CcSEcCtD
Levobupivacaine—Constipation—Carmustine—melanoma	0.000167	0.00201	CcSEcCtD
Levobupivacaine—Pain—Carmustine—melanoma	0.000167	0.00201	CcSEcCtD
Levobupivacaine—Dyspepsia—Temozolomide—melanoma	0.000167	0.002	CcSEcCtD
Levobupivacaine—Abdominal pain—Dactinomycin—melanoma	0.000165	0.00198	CcSEcCtD
Levobupivacaine—Body temperature increased—Dactinomycin—melanoma	0.000165	0.00198	CcSEcCtD
Levobupivacaine—Hypersensitivity—Bleomycin—melanoma	0.000165	0.00198	CcSEcCtD
Levobupivacaine—Decreased appetite—Temozolomide—melanoma	0.000165	0.00197	CcSEcCtD
Levobupivacaine—Cardiac disorder—Docetaxel—melanoma	0.000164	0.00197	CcSEcCtD
Levobupivacaine—Flushing—Docetaxel—melanoma	0.000164	0.00197	CcSEcCtD
Levobupivacaine—Gastrointestinal disorder—Temozolomide—melanoma	0.000163	0.00196	CcSEcCtD
Levobupivacaine—Constipation—Temozolomide—melanoma	0.000162	0.00194	CcSEcCtD
Levobupivacaine—Pain—Temozolomide—melanoma	0.000162	0.00194	CcSEcCtD
Levobupivacaine—Feeling abnormal—Carmustine—melanoma	0.000161	0.00194	CcSEcCtD
Levobupivacaine—Asthenia—Bleomycin—melanoma	0.000161	0.00193	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Carmustine—melanoma	0.00016	0.00192	CcSEcCtD
Levobupivacaine—Chills—Docetaxel—melanoma	0.000159	0.00191	CcSEcCtD
Levobupivacaine—Pruritus—Bleomycin—melanoma	0.000159	0.0019	CcSEcCtD
Levobupivacaine—Arrhythmia—Docetaxel—melanoma	0.000158	0.0019	CcSEcCtD
Levobupivacaine—Feeling abnormal—Temozolomide—melanoma	0.000156	0.00187	CcSEcCtD
Levobupivacaine—Mental disorder—Docetaxel—melanoma	0.000155	0.00186	CcSEcCtD
Levobupivacaine—Abdominal pain—Carmustine—melanoma	0.000155	0.00186	CcSEcCtD
Levobupivacaine—Body temperature increased—Carmustine—melanoma	0.000155	0.00186	CcSEcCtD
Levobupivacaine—Gastrointestinal pain—Temozolomide—melanoma	0.000155	0.00186	CcSEcCtD
Levobupivacaine—Erythema—Docetaxel—melanoma	0.000154	0.00185	CcSEcCtD
Levobupivacaine—Malnutrition—Docetaxel—melanoma	0.000154	0.00185	CcSEcCtD
Levobupivacaine—Hypersensitivity—Dactinomycin—melanoma	0.000154	0.00185	CcSEcCtD
Levobupivacaine—Urticaria—Temozolomide—melanoma	0.00015	0.0018	CcSEcCtD
Levobupivacaine—Asthenia—Dactinomycin—melanoma	0.00015	0.0018	CcSEcCtD
Levobupivacaine—Body temperature increased—Temozolomide—melanoma	0.00015	0.00179	CcSEcCtD
Levobupivacaine—Abdominal pain—Temozolomide—melanoma	0.00015	0.00179	CcSEcCtD
Levobupivacaine—Back pain—Docetaxel—melanoma	0.000149	0.00179	CcSEcCtD
Levobupivacaine—Muscle spasms—Docetaxel—melanoma	0.000148	0.00178	CcSEcCtD
Levobupivacaine—Tocainide—ALB—melanoma	0.000148	0.0252	CrCbGaD
Levobupivacaine—Hypersensitivity—Carmustine—melanoma	0.000144	0.00173	CcSEcCtD
Levobupivacaine—Diarrhoea—Dactinomycin—melanoma	0.000143	0.00172	CcSEcCtD
Levobupivacaine—Vomiting—Bleomycin—melanoma	0.000143	0.00171	CcSEcCtD
Levobupivacaine—Anaemia—Docetaxel—melanoma	0.000143	0.00171	CcSEcCtD
Levobupivacaine—Asthenia—Carmustine—melanoma	0.000141	0.00169	CcSEcCtD
Levobupivacaine—Hypersensitivity—Temozolomide—melanoma	0.000139	0.00167	CcSEcCtD
Levobupivacaine—Syncope—Docetaxel—melanoma	0.000138	0.00166	CcSEcCtD
Levobupivacaine—Palpitations—Docetaxel—melanoma	0.000136	0.00163	CcSEcCtD
Levobupivacaine—Asthenia—Temozolomide—melanoma	0.000136	0.00163	CcSEcCtD
Levobupivacaine—Loss of consciousness—Docetaxel—melanoma	0.000136	0.00163	CcSEcCtD
Levobupivacaine—Cough—Docetaxel—melanoma	0.000135	0.00161	CcSEcCtD
Levobupivacaine—Diarrhoea—Carmustine—melanoma	0.000134	0.00161	CcSEcCtD
Levobupivacaine—Pruritus—Temozolomide—melanoma	0.000134	0.00161	CcSEcCtD
Levobupivacaine—Convulsion—Docetaxel—melanoma	0.000134	0.0016	CcSEcCtD
Levobupivacaine—Nausea—Bleomycin—melanoma	0.000133	0.0016	CcSEcCtD
Levobupivacaine—Hypertension—Docetaxel—melanoma	0.000133	0.0016	CcSEcCtD
Levobupivacaine—Vomiting—Dactinomycin—melanoma	0.000133	0.0016	CcSEcCtD
Levobupivacaine—Arthralgia—Docetaxel—melanoma	0.000131	0.00157	CcSEcCtD
Levobupivacaine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00013	0.00156	CcSEcCtD
Levobupivacaine—Dizziness—Carmustine—melanoma	0.00013	0.00155	CcSEcCtD
Levobupivacaine—Diarrhoea—Temozolomide—melanoma	0.000129	0.00155	CcSEcCtD
Levobupivacaine—Confusional state—Docetaxel—melanoma	0.000127	0.00152	CcSEcCtD
Levobupivacaine—Oedema—Docetaxel—melanoma	0.000126	0.00151	CcSEcCtD
Levobupivacaine—Anaphylactic shock—Docetaxel—melanoma	0.000126	0.00151	CcSEcCtD
Levobupivacaine—Dizziness—Temozolomide—melanoma	0.000125	0.0015	CcSEcCtD
Levobupivacaine—Infection—Docetaxel—melanoma	0.000125	0.0015	CcSEcCtD
Levobupivacaine—Vomiting—Carmustine—melanoma	0.000125	0.00149	CcSEcCtD
Levobupivacaine—Nausea—Dactinomycin—melanoma	0.000124	0.00149	CcSEcCtD
Levobupivacaine—Shock—Docetaxel—melanoma	0.000124	0.00149	CcSEcCtD
Levobupivacaine—Nervous system disorder—Docetaxel—melanoma	0.000123	0.00148	CcSEcCtD
Levobupivacaine—Tachycardia—Docetaxel—melanoma	0.000123	0.00147	CcSEcCtD
Levobupivacaine—Headache—Carmustine—melanoma	0.000123	0.00147	CcSEcCtD
Levobupivacaine—Skin disorder—Docetaxel—melanoma	0.000122	0.00147	CcSEcCtD
Levobupivacaine—Vomiting—Temozolomide—melanoma	0.00012	0.00144	CcSEcCtD
Levobupivacaine—Headache—Temozolomide—melanoma	0.000119	0.00142	CcSEcCtD
Levobupivacaine—Hypotension—Docetaxel—melanoma	0.000118	0.00141	CcSEcCtD
Levobupivacaine—Nausea—Carmustine—melanoma	0.000116	0.0014	CcSEcCtD
Levobupivacaine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000115	0.00138	CcSEcCtD
Levobupivacaine—Insomnia—Docetaxel—melanoma	0.000114	0.00137	CcSEcCtD
Levobupivacaine—Paraesthesia—Docetaxel—melanoma	0.000113	0.00136	CcSEcCtD
Levobupivacaine—Nausea—Temozolomide—melanoma	0.000112	0.00135	CcSEcCtD
Levobupivacaine—Dyspnoea—Docetaxel—melanoma	0.000112	0.00135	CcSEcCtD
Levobupivacaine—Somnolence—Docetaxel—melanoma	0.000112	0.00134	CcSEcCtD
Levobupivacaine—Dyspepsia—Docetaxel—melanoma	0.000111	0.00133	CcSEcCtD
Levobupivacaine—Decreased appetite—Docetaxel—melanoma	0.000109	0.00131	CcSEcCtD
Levobupivacaine—Lidocaine—ABCB1—melanoma	0.000109	0.0186	CrCbGaD
Levobupivacaine—Gastrointestinal disorder—Docetaxel—melanoma	0.000109	0.0013	CcSEcCtD
Levobupivacaine—Pain—Docetaxel—melanoma	0.000108	0.00129	CcSEcCtD
Levobupivacaine—Constipation—Docetaxel—melanoma	0.000108	0.00129	CcSEcCtD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	0.000106	0.00262	CbGpPWpGaD
Levobupivacaine—SCN4A—L1CAM interactions—MAPK3—melanoma	0.000105	0.00261	CbGpPWpGaD
Levobupivacaine—Feeling abnormal—Docetaxel—melanoma	0.000104	0.00124	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—ITGB1—melanoma	0.000103	0.00257	CbGpPWpGaD
Levobupivacaine—Gastrointestinal pain—Docetaxel—melanoma	0.000103	0.00123	CcSEcCtD
Levobupivacaine—SCN10A—L1CAM interactions—MAPK3—melanoma	0.000101	0.00252	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—melanoma	0.000101	0.0025	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—melanoma	0.000101	0.0025	CbGpPWpGaD
Levobupivacaine—CYP1A2—Tryptophan metabolism—CYP1B1—melanoma	0.000101	0.0025	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—PAX6—melanoma	0.000101	0.0025	CbGpPWpGaD
Levobupivacaine—SCN4A—L1CAM interactions—MAPK1—melanoma	0.0001	0.00248	CbGpPWpGaD
Levobupivacaine—SCN4A—L1CAM interactions—EGFR—melanoma	0.0001	0.00248	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—ITGB1—melanoma	9.97e-05	0.00247	CbGpPWpGaD
Levobupivacaine—Body temperature increased—Docetaxel—melanoma	9.95e-05	0.00119	CcSEcCtD
Levobupivacaine—Abdominal pain—Docetaxel—melanoma	9.95e-05	0.00119	CcSEcCtD
Levobupivacaine—CYP1A2—Estrogen Receptor Pathway—STAT3—melanoma	9.74e-05	0.00242	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—PAX6—melanoma	9.72e-05	0.00241	CbGpPWpGaD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	9.69e-05	0.0024	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—UGT2B10—melanoma	9.66e-05	0.0024	CbGpPWpGaD
Levobupivacaine—SCN10A—L1CAM interactions—MAPK1—melanoma	9.64e-05	0.00239	CbGpPWpGaD
Levobupivacaine—SCN10A—L1CAM interactions—EGFR—melanoma	9.64e-05	0.00239	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP17A1—melanoma	9.56e-05	0.00237	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—CYP1B1—melanoma	9.43e-05	0.00234	CbGpPWpGaD
Levobupivacaine—Hypersensitivity—Docetaxel—melanoma	9.27e-05	0.00111	CcSEcCtD
Levobupivacaine—Asthenia—Docetaxel—melanoma	9.03e-05	0.00108	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—ITGB3—melanoma	8.96e-05	0.00223	CbGpPWpGaD
Levobupivacaine—Pruritus—Docetaxel—melanoma	8.9e-05	0.00107	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—MAP2K2—melanoma	8.76e-05	0.00218	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—ITGB3—melanoma	8.64e-05	0.00215	CbGpPWpGaD
Levobupivacaine—Diarrhoea—Docetaxel—melanoma	8.61e-05	0.00103	CcSEcCtD
Levobupivacaine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	8.57e-05	0.00213	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MAP2K2—melanoma	8.45e-05	0.0021	CbGpPWpGaD
Levobupivacaine—Dizziness—Docetaxel—melanoma	8.32e-05	0.000998	CcSEcCtD
Levobupivacaine—SCN4A—Axon guidance—RAC1—melanoma	8.31e-05	0.00206	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—melanoma	8.16e-05	0.00203	CbGpPWpGaD
Levobupivacaine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	8.15e-05	0.00202	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	8.14e-05	0.00202	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—AKT3—melanoma	8.12e-05	0.00202	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ITGAV—melanoma	8.12e-05	0.00202	CbGpPWpGaD
Levobupivacaine—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—melanoma	8.05e-05	0.002	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—RAC1—melanoma	8.01e-05	0.00199	CbGpPWpGaD
Levobupivacaine—Vomiting—Docetaxel—melanoma	8e-05	0.00096	CcSEcCtD
Levobupivacaine—CYP1A2—Metapathway biotransformation—AKR1B10—melanoma	7.95e-05	0.00197	CbGpPWpGaD
Levobupivacaine—Headache—Docetaxel—melanoma	7.88e-05	0.000946	CcSEcCtD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	7.85e-05	0.00195	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ITGAV—melanoma	7.83e-05	0.00195	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—AKT3—melanoma	7.83e-05	0.00195	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—E2F1—melanoma	7.8e-05	0.00194	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tryptophan metabolism—CYP1B1—melanoma	7.78e-05	0.00193	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—KDR—melanoma	7.62e-05	0.00189	CbGpPWpGaD
Levobupivacaine—Nausea—Docetaxel—melanoma	7.48e-05	0.000897	CcSEcCtD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	7.47e-05	0.00186	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MET—melanoma	7.46e-05	0.00185	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ITGB1—melanoma	7.38e-05	0.00183	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—melanoma	7.38e-05	0.00183	CbGpPWpGaD
Levobupivacaine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	7.36e-05	0.00183	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—KDR—melanoma	7.35e-05	0.00182	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MET—melanoma	7.19e-05	0.00179	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ITGB1—melanoma	7.11e-05	0.00177	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CDK2—melanoma	6.73e-05	0.00167	CbGpPWpGaD
Levobupivacaine—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	6.61e-05	0.00164	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ITGB3—melanoma	6.4e-05	0.00159	CbGpPWpGaD
Levobupivacaine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	6.29e-05	0.00156	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MAP2K2—melanoma	6.25e-05	0.00155	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MMP2—melanoma	6.22e-05	0.00154	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MAP2K1—melanoma	6.21e-05	0.00154	CbGpPWpGaD
Levobupivacaine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—melanoma	6.21e-05	0.00154	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ITGB3—melanoma	6.17e-05	0.00153	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—AKR1B10—melanoma	6.14e-05	0.00152	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	6.06e-05	0.0015	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MAP2K2—melanoma	6.03e-05	0.0015	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MMP2—melanoma	6e-05	0.00149	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MAP2K1—melanoma	5.99e-05	0.00149	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—RAC1—melanoma	5.93e-05	0.00147	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—RAC1—melanoma	5.72e-05	0.00142	CbGpPWpGaD
Levobupivacaine—CYP1A2—Melatonin metabolism and effects—NFKB1—melanoma	5.7e-05	0.00142	CbGpPWpGaD
Levobupivacaine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	5.68e-05	0.00141	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—melanoma	5.53e-05	0.00137	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—ERBB2—melanoma	5.45e-05	0.00135	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—KDR—melanoma	5.44e-05	0.00135	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MET—melanoma	5.32e-05	0.00132	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—CDK4—melanoma	5.32e-05	0.00132	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—MAP2K1—melanoma	5.3e-05	0.00132	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—ERBB2—melanoma	5.26e-05	0.00131	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—ACER3—melanoma	5.25e-05	0.0013	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—KDR—melanoma	5.24e-05	0.0013	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MET—melanoma	5.13e-05	0.00127	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—CDK4—melanoma	5.13e-05	0.00127	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—NOTCH1—melanoma	5.12e-05	0.00127	CbGpPWpGaD
Levobupivacaine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	5.1e-05	0.00127	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—NOTCH1—melanoma	4.94e-05	0.00123	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—PPARG—melanoma	4.84e-05	0.0012	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	4.74e-05	0.00118	CbGpPWpGaD
Levobupivacaine—CYP1A2—Tryptophan metabolism—MDM2—melanoma	4.71e-05	0.00117	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MMP9—melanoma	4.68e-05	0.00116	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—PPARG—melanoma	4.66e-05	0.00116	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—melanoma	4.54e-05	0.00113	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MMP9—melanoma	4.51e-05	0.00112	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MMP2—melanoma	4.44e-05	0.0011	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MAP2K1—melanoma	4.43e-05	0.0011	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	4.3e-05	0.00107	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—melanoma	4.3e-05	0.00107	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MMP2—melanoma	4.28e-05	0.00106	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MAP2K1—melanoma	4.28e-05	0.00106	CbGpPWpGaD
Levobupivacaine—CYP1A2—Arachidonic acid metabolism—PTGS2—melanoma	4.25e-05	0.00106	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—FGF2—melanoma	4.22e-05	0.00105	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	4.21e-05	0.00105	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—VEGFA—melanoma	4.2e-05	0.00104	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—CYP17A1—melanoma	4.17e-05	0.00104	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—NRAS—melanoma	4.15e-05	0.00103	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—CYP17A1—melanoma	4.11e-05	0.00102	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—FGF2—melanoma	4.07e-05	0.00101	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—VEGFA—melanoma	4.05e-05	0.00101	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—NRAS—melanoma	4e-05	0.000993	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—melanoma	3.97e-05	0.000986	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MAPK3—melanoma	3.97e-05	0.000986	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—melanoma	3.94e-05	0.000979	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—ERBB2—melanoma	3.89e-05	0.000966	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MAPK3—melanoma	3.83e-05	0.000951	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—MAPK1—melanoma	3.78e-05	0.000938	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—EGFR—melanoma	3.78e-05	0.000938	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—ERBB2—melanoma	3.75e-05	0.000931	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—MAPK1—melanoma	3.64e-05	0.000905	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—EGFR—melanoma	3.64e-05	0.000905	CbGpPWpGaD
Levobupivacaine—CYP3A4—Tryptophan metabolism—MDM2—melanoma	3.64e-05	0.000903	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—melanoma	3.58e-05	0.000889	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—KRAS—melanoma	3.57e-05	0.000886	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—melanoma	3.54e-05	0.000878	CbGpPWpGaD
Levobupivacaine—CYP1A2—Biological oxidations—CYP1B1—melanoma	3.51e-05	0.000872	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metapathway biotransformation—CYP1B1—melanoma	3.46e-05	0.00086	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—KRAS—melanoma	3.44e-05	0.000855	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—CTNNB1—melanoma	3.4e-05	0.000845	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MMP9—melanoma	3.34e-05	0.000828	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—NFKB1—melanoma	3.3e-05	0.00082	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—melanoma	3.29e-05	0.000818	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—CTNNB1—melanoma	3.28e-05	0.000815	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—melanoma	3.22e-05	0.0008	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	3.22e-05	0.0008	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—melanoma	3.22e-05	0.0008	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP17A1—melanoma	3.22e-05	0.000799	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MMP9—melanoma	3.22e-05	0.000799	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PIP4K2A—melanoma	3.18e-05	0.00079	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—NFKB1—melanoma	3.18e-05	0.00079	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP17A1—melanoma	3.17e-05	0.000788	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	3.07e-05	0.000762	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—melanoma	3.07e-05	0.000762	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—melanoma	3.04e-05	0.000756	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—HRAS—melanoma	3.03e-05	0.000753	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—VEGFA—melanoma	3e-05	0.000744	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—STAT3—melanoma	2.97e-05	0.000737	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—NRAS—melanoma	2.96e-05	0.000735	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—HRAS—melanoma	2.93e-05	0.000726	CbGpPWpGaD
Levobupivacaine—SCN4A—Axon guidance—IL6—melanoma	2.9e-05	0.000721	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—VEGFA—melanoma	2.89e-05	0.000717	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—STAT3—melanoma	2.86e-05	0.00071	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—NRAS—melanoma	2.85e-05	0.000709	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MAPK3—melanoma	2.83e-05	0.000704	CbGpPWpGaD
Levobupivacaine—SCN10A—Axon guidance—IL6—melanoma	2.8e-05	0.000695	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MAPK3—melanoma	2.73e-05	0.000679	CbGpPWpGaD
Levobupivacaine—CYP3A4—Biological oxidations—CYP1B1—melanoma	2.71e-05	0.000673	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—MAPK1—melanoma	2.7e-05	0.00067	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—EGFR—melanoma	2.7e-05	0.000669	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	2.67e-05	0.000663	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CUBN—melanoma	2.66e-05	0.00066	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—MAPK1—melanoma	2.6e-05	0.000646	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—EGFR—melanoma	2.6e-05	0.000646	CbGpPWpGaD
Levobupivacaine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—melanoma	2.59e-05	0.000642	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—TNF—melanoma	2.57e-05	0.000638	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—KRAS—melanoma	2.55e-05	0.000632	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—GPAM—melanoma	2.49e-05	0.000617	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—TNF—melanoma	2.48e-05	0.000615	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—KRAS—melanoma	2.46e-05	0.00061	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ACER3—melanoma	2.34e-05	0.000581	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—HRAS—melanoma	2.17e-05	0.000538	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—UGT2B10—melanoma	2.14e-05	0.000531	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	2.11e-05	0.000525	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—HRAS—melanoma	2.09e-05	0.000518	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—IL6—melanoma	2.07e-05	0.000515	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—IL6—melanoma	2e-05	0.000496	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—HS3ST5—melanoma	1.99e-05	0.000494	CbGpPWpGaD
Levobupivacaine—SCN4A—Developmental Biology—AKT1—melanoma	1.91e-05	0.000475	CbGpPWpGaD
Levobupivacaine—SCN10A—Developmental Biology—AKT1—melanoma	1.84e-05	0.000458	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ACER3—melanoma	1.81e-05	0.000448	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—UGT2B10—melanoma	1.65e-05	0.00041	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.6e-05	0.000398	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—HS3ST5—melanoma	1.54e-05	0.000381	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PLCB4—melanoma	1.51e-05	0.000374	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—FASN—melanoma	1.48e-05	0.000367	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PIP4K2A—melanoma	1.42e-05	0.000352	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—SLC6A11—melanoma	1.42e-05	0.000352	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—MTAP—melanoma	1.38e-05	0.000342	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.35e-05	0.000335	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—LUM—melanoma	1.23e-05	0.000305	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PHGDH—melanoma	1.23e-05	0.000305	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—HPSE—melanoma	1.21e-05	0.000299	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CUBN—melanoma	1.18e-05	0.000294	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PLCB4—melanoma	1.16e-05	0.000289	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—SDHD—melanoma	1.14e-05	0.000284	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CSPG4—melanoma	1.14e-05	0.000284	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—BSG—melanoma	1.14e-05	0.000284	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GPAM—melanoma	1.11e-05	0.000275	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—SLC6A11—melanoma	1.09e-05	0.000272	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PIP4K2A—melanoma	1.09e-05	0.000272	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—MTAP—melanoma	1.06e-05	0.000264	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—LUM—melanoma	9.49e-06	0.000236	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PHGDH—melanoma	9.49e-06	0.000236	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PLA2G6—melanoma	9.41e-06	0.000234	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—HPSE—melanoma	9.3e-06	0.000231	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CUBN—melanoma	9.13e-06	0.000227	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—SDHD—melanoma	8.82e-06	0.000219	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—BSG—melanoma	8.82e-06	0.000219	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CSPG4—melanoma	8.82e-06	0.000219	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GPAM—melanoma	8.54e-06	0.000212	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—VCAN—melanoma	8.45e-06	0.00021	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	8e-06	0.000199	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	7.72e-06	0.000192	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PLA2G6—melanoma	7.26e-06	0.00018	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP17A1—melanoma	7.13e-06	0.000177	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	7.03e-06	0.000175	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	6.94e-06	0.000172	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GNA11—melanoma	6.74e-06	0.000167	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—FASN—melanoma	6.59e-06	0.000164	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—VCAN—melanoma	6.52e-06	0.000162	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—SLC5A5—melanoma	6.48e-06	0.000161	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—GNAQ—melanoma	6.26e-06	0.000155	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CD44—melanoma	6.26e-06	0.000155	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.13e-06	0.000152	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.08e-06	0.000151	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—CYP1B1—melanoma	6e-06	0.000149	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP17A1—melanoma	5.5e-06	0.000137	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.3e-06	0.000132	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GNA11—melanoma	5.2e-06	0.000129	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—FASN—melanoma	5.09e-06	0.000126	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—SLC5A5—melanoma	5e-06	0.000124	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ABCB1—melanoma	4.94e-06	0.000123	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CD44—melanoma	4.83e-06	0.00012	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—GNAQ—melanoma	4.83e-06	0.00012	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—CYP1B1—melanoma	4.63e-06	0.000115	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PRKCA—melanoma	4.55e-06	0.000113	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ERCC2—melanoma	4.51e-06	0.000112	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ABCB1—melanoma	3.82e-06	9.47e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.74e-06	9.28e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PIK3CG—melanoma	3.56e-06	8.85e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PRKCA—melanoma	3.51e-06	8.72e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ERCC2—melanoma	3.48e-06	8.65e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PPARG—melanoma	3.44e-06	8.54e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PIK3CD—melanoma	3.13e-06	7.78e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—ALB—melanoma	3.09e-06	7.68e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PIK3CG—melanoma	2.75e-06	6.83e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PIK3CB—melanoma	2.73e-06	6.78e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PTGS2—melanoma	2.71e-06	6.72e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PPARG—melanoma	2.65e-06	6.59e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PIK3CD—melanoma	2.42e-06	6e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—ALB—melanoma	2.39e-06	5.93e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PTEN—melanoma	2.36e-06	5.86e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PIK3CB—melanoma	2.11e-06	5.23e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PTGS2—melanoma	2.09e-06	5.18e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PTEN—melanoma	1.82e-06	4.52e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—PIK3CA—melanoma	1.66e-06	4.13e-05	CbGpPWpGaD
Levobupivacaine—CYP1A2—Metabolism—AKT1—melanoma	1.36e-06	3.38e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—PIK3CA—melanoma	1.28e-06	3.19e-05	CbGpPWpGaD
Levobupivacaine—CYP3A4—Metabolism—AKT1—melanoma	1.05e-06	2.61e-05	CbGpPWpGaD
